RU2144356C1 - Композиция для инъекций на основе таксоидов - Google Patents
Композиция для инъекций на основе таксоидов Download PDFInfo
- Publication number
- RU2144356C1 RU2144356C1 RU95113494A RU95113494A RU2144356C1 RU 2144356 C1 RU2144356 C1 RU 2144356C1 RU 95113494 A RU95113494 A RU 95113494A RU 95113494 A RU95113494 A RU 95113494A RU 2144356 C1 RU2144356 C1 RU 2144356C1
- Authority
- RU
- Russia
- Prior art keywords
- solution
- composition according
- ethanol
- radical
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 238000002347 injection Methods 0.000 title claims abstract description 6
- 239000007924 injection Substances 0.000 title claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000000243 solution Substances 0.000 claims abstract description 35
- 239000004094 surface-active agent Substances 0.000 claims abstract description 22
- 229940123237 Taxane Drugs 0.000 claims abstract description 5
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 238000007865 diluting Methods 0.000 claims abstract description 3
- 125000003277 amino group Chemical group 0.000 claims abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000000654 additive Substances 0.000 claims description 12
- 230000000996 additive effect Effects 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical group C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229940068965 polysorbates Drugs 0.000 claims description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 abstract description 6
- 229960001592 paclitaxel Drugs 0.000 abstract description 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract description 5
- 206010002199 Anaphylactic shock Diseases 0.000 abstract description 3
- 208000003455 anaphylaxis Diseases 0.000 abstract description 3
- 230000000719 anti-leukaemic effect Effects 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 235000015110 jellies Nutrition 0.000 abstract 1
- 239000008274 jelly Substances 0.000 abstract 1
- 125000002456 taxol group Chemical group 0.000 abstract 1
- 230000010412 perfusion Effects 0.000 description 12
- 239000008389 polyethoxylated castor oil Substances 0.000 description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229940063683 taxotere Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- 239000012452 mother liquor Substances 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 0 *[C@]([C@](C(O)=O)O)c1ccccc1 Chemical compound *[C@]([C@](C(O)=O)O)c1ccccc1 0.000 description 2
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- -1 glyceride fatty acid esters Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9214501A FR2698543B1 (fr) | 1992-12-02 | 1992-12-02 | Nouvelles compositions à base de taxoides. |
| FR9214501 | 1992-12-02 | ||
| PCT/FR1993/001166 WO1994012171A1 (fr) | 1992-12-02 | 1993-11-26 | Compositions injectables a base de derives des taxanes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU95113494A RU95113494A (ru) | 1997-12-10 |
| RU2144356C1 true RU2144356C1 (ru) | 2000-01-20 |
Family
ID=9436137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU95113494A RU2144356C1 (ru) | 1992-12-02 | 1993-11-26 | Композиция для инъекций на основе таксоидов |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5438072A (enExample) |
| EP (1) | EP0671912B1 (enExample) |
| JP (1) | JP3689791B2 (enExample) |
| KR (1) | KR100330316B1 (enExample) |
| CN (2) | CN1090170A (enExample) |
| AT (1) | ATE190838T1 (enExample) |
| AU (1) | AU691476B2 (enExample) |
| CA (1) | CA2150576C (enExample) |
| CZ (1) | CZ284080B6 (enExample) |
| DE (2) | DE69328192D1 (enExample) |
| DK (1) | DK0671912T3 (enExample) |
| ES (1) | ES2145115T4 (enExample) |
| FI (1) | FI113619B (enExample) |
| FR (1) | FR2698543B1 (enExample) |
| GE (1) | GEP19991856B (enExample) |
| GR (1) | GR3032828T3 (enExample) |
| HU (1) | HU222833B1 (enExample) |
| MX (1) | MX9306986A (enExample) |
| NO (1) | NO314436B1 (enExample) |
| NZ (1) | NZ258150A (enExample) |
| PL (1) | PL174334B1 (enExample) |
| PT (1) | PT671912E (enExample) |
| RU (1) | RU2144356C1 (enExample) |
| SK (1) | SK281558B6 (enExample) |
| TW (1) | TW271395B (enExample) |
| WO (1) | WO1994012171A1 (enExample) |
| YU (1) | YU49092B (enExample) |
| ZA (1) | ZA938936B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2428175C2 (ru) * | 2008-06-02 | 2011-09-10 | Закрытое Акционерное Общество "Биокад" | Способ получения парентерального фармацевтического раствора |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994341A (en) * | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| DE69435341D1 (de) | 1993-07-19 | 2011-05-05 | Angiotech Pharm Inc | Herstellungsmethode eines Stents mit anti-angiogener Zusammensetzung |
| US5681846A (en) * | 1995-03-17 | 1997-10-28 | Board Of Regents, The University Of Texas System | Extended stability formulations for paclitaxel |
| US6245805B1 (en) | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| US6395770B1 (en) * | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
| US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| AU724842B2 (en) * | 1995-12-21 | 2000-09-28 | Genelabs Technologies, Inc. | Taxane composition and method |
| KR100191446B1 (ko) * | 1996-05-02 | 1999-06-15 | 송영욱 | 파클리탁셀 함유 전신성 홍반성 낭창치료제 |
| ES2248847T3 (es) | 1996-05-24 | 2006-03-16 | Angiotech Pharmaceuticals, Inc. | Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo. |
| KR100330373B1 (ko) * | 1996-05-28 | 2002-11-07 | 주식회사한국신약 | 탁솔을 함유한 주사용 약제 조성물 |
| US5877205A (en) * | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
| KR100358934B1 (ko) * | 1996-09-13 | 2003-01-29 | 주식회사한국신약 | 탁솔을함유한주사용약제조성물 |
| DE19655141C5 (de) | 1996-11-08 | 2013-12-05 | Eppendorf Ag | Gradienten-Temperierblock für Laborthermostaten |
| US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
| ES2285743T3 (es) | 1996-12-30 | 2007-11-16 | Battelle Memorial Institute | Uso de un farmaco anticancerigeno no encapsulado para la preparacion de una formulacion para tratar neoplasias mediante inhlacion. |
| BR9808697A (pt) | 1997-04-28 | 2000-07-11 | Rhone Poulenc Rorer Sa | Processo para inibir o crescimento de um tumor, vetor de adenovìrus defeituoso, vetor de vìrus, uso do mesmo, e, composição farmacêutica |
| EP0998279B1 (en) * | 1997-05-30 | 2002-10-16 | Man Woo Han | Pharmaceutical injection solution containing taxol |
| CN1101677C (zh) * | 1997-05-30 | 2003-02-19 | 韩万愚 | 含有紫杉醇的药用注射溶液 |
| BE1011216A3 (fr) * | 1997-06-13 | 1999-06-01 | Thissen En Abrege L T B Lab | Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition. |
| US5925776A (en) * | 1997-12-24 | 1999-07-20 | Schein Pharmacetical, Inc. | Polyethoxylated castor oil, process of making the same and formulations thereof |
| GB9803448D0 (en) * | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| US5922754A (en) * | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
| US6071952A (en) * | 1998-12-02 | 2000-06-06 | Mylan Pharmaceuticals, Inc. | Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents |
| FR2794771B1 (fr) | 1999-06-11 | 2001-08-10 | Aventis Pharma Sa | Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis) |
| JP4776843B2 (ja) | 1999-10-01 | 2011-09-21 | イムノゲン インコーポレーティッド | 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法 |
| NZ518847A (en) * | 1999-11-15 | 2004-02-27 | Pharma Mar S | Aplidine treatment of cancers |
| PL350075A1 (en) * | 2000-02-02 | 2002-11-04 | Univ Florida State Res Found | Taxane formulations having improved solubility |
| KR20010100194A (ko) * | 2000-03-13 | 2001-11-14 | 박호군 | 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법 |
| US6919370B2 (en) * | 2000-11-28 | 2005-07-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
| CN1555253A (zh) * | 2001-09-13 | 2004-12-15 | ������ѧ�����о�Ժ | 化疗栓塞用紫杉醇的油性组合物、制剂及它们的制造方法 |
| US20050004012A1 (en) * | 2001-10-19 | 2005-01-06 | Ramon Mangues | Use of aplidine for the treatment of pancreatic cancer |
| AU2002357012A1 (en) * | 2001-11-27 | 2003-06-10 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
| US8313760B2 (en) | 2002-05-24 | 2012-11-20 | Angiotech International Ag | Compositions and methods for coating medical implants |
| CA2484761C (en) | 2002-05-24 | 2010-11-09 | Angiotech International Ag | Compositions and methods for coating medical implants |
| KR100533458B1 (ko) * | 2002-07-20 | 2005-12-07 | 대화제약 주식회사 | 파클리탁셀의 가용화용 조성물 및 그의 제조 방법 |
| AU2003278764C1 (en) | 2002-09-06 | 2010-09-16 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| US20080220074A1 (en) * | 2002-10-04 | 2008-09-11 | Elan Corporation Plc | Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same |
| US20050152941A1 (en) * | 2003-11-20 | 2005-07-14 | Angiotech International Ag | Soft tissue implants and anti-scarring agents |
| US20080113028A1 (en) | 2004-09-22 | 2008-05-15 | Kazuhisa Shimizu | Novel Block Copolymer, Micelle Preparation, And Anticancer Agent Containing The Same As Active Ingredient |
| AU2005100176A4 (en) * | 2005-03-01 | 2005-04-07 | Gym Tv Pty Ltd | Garbage bin clip |
| KR20080030024A (ko) | 2005-06-17 | 2008-04-03 | 호스피라 오스트레일리아 피티와이 리미티드 | 도세탁셀의 약제학적 액상제제 |
| GB0517092D0 (en) * | 2005-08-19 | 2005-09-28 | Novartis Ag | New compositions containing taxane derivatives |
| AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| BRPI0600194A (pt) | 2006-01-30 | 2007-10-23 | Quiral Quimica Do Brasil S A | composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas |
| CN101023940A (zh) * | 2006-02-20 | 2007-08-29 | 郝守祝 | 一种紫杉烷类化合物的药用组合物、制备方法及用途 |
| WO2007111211A1 (ja) * | 2006-03-28 | 2007-10-04 | Nippon Kayaku Kabushiki Kaisha | タキサン類の高分子結合体 |
| RU2447095C2 (ru) | 2006-05-18 | 2012-04-10 | Ниппон Каяку Кабусики Кайся | Высокомолекулярный конъюгат подофиллотоксинов |
| JP5548364B2 (ja) * | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
| JP5503872B2 (ja) | 2006-11-06 | 2014-05-28 | 日本化薬株式会社 | 核酸系代謝拮抗剤の高分子誘導体 |
| EP2090607B1 (en) | 2006-11-08 | 2015-05-20 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
| AU2008205330B2 (en) | 2007-01-08 | 2014-07-03 | Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | SLCO1B3 genotype |
| CZ200756A3 (cs) * | 2007-01-23 | 2008-07-30 | Heaton, A. S. | Dvousložková farmaceutická kompozice obsahující taxan |
| JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス， インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
| CN101244053B (zh) * | 2007-02-16 | 2010-12-08 | 石药集团中奇制药技术（石家庄）有限公司 | 以多西他赛为主组分的新的分散体系 |
| US20080262078A1 (en) * | 2007-04-20 | 2008-10-23 | Namdeo Alok B | Pharmaceutical Compositions |
| JP2010530872A (ja) * | 2007-06-22 | 2010-09-16 | サイドース・エルエルシー | Ｔｗｅｅｎ８０を含まないドセタキセル可溶化製剤 |
| JP5349318B2 (ja) | 2007-09-28 | 2013-11-20 | 日本化薬株式会社 | ステロイド類の高分子結合体 |
| CN101396354B (zh) * | 2007-09-30 | 2010-12-01 | 江苏恒瑞医药股份有限公司 | 一种稳定的塔三烷类化合物液体组合物及其制备方法和其应用 |
| WO2009047794A2 (en) * | 2007-10-01 | 2009-04-16 | Intas Pharmaceuticals Limited | Taxane derivative composition |
| AR063111A1 (es) * | 2007-10-03 | 2008-12-30 | Eriochem Sa | Una formulacion farmaceutica de taxano |
| FR2922107B1 (fr) * | 2007-10-10 | 2010-02-26 | Aventis Pharma Sa | Nouvelles compositions a base de taxoides |
| CA2718233A1 (en) | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
| DK2249825T3 (en) | 2008-03-14 | 2016-01-11 | Bionumerik Pharmaceuticals Inc | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| CN110251670B (zh) | 2008-03-18 | 2023-11-14 | 健泰科生物技术公司 | 抗her2抗体-药物偶联物和化疗剂的组合，及使用方法 |
| JP5687899B2 (ja) * | 2008-03-18 | 2015-03-25 | 日本化薬株式会社 | 生理活性物質の高分子結合体 |
| US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
| ES2344674B1 (es) * | 2008-08-07 | 2011-06-29 | Gp Pharm, S.A. | Composicion farmaceutica inyectable de taxanos. |
| EP2331140B1 (en) | 2008-08-11 | 2018-07-04 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| US8541360B2 (en) * | 2008-11-19 | 2013-09-24 | Ben Venue Laboratories, Inc. | Parenteral formulations comprising sugar-based esters and ethers |
| CA2754909A1 (en) | 2009-03-11 | 2010-09-16 | Ambit Biosciences Corp. | Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment |
| EP2431403B1 (en) | 2009-05-15 | 2016-09-28 | Nipponkayaku Kabushikikaisha | Polymer conjugate of bioactive substance having hydroxy group |
| US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
| US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| US8476310B2 (en) | 2009-10-19 | 2013-07-02 | Scidose Llc | Docetaxel formulations with lipoic acid |
| US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
| MY164086A (en) | 2009-10-29 | 2017-11-30 | Aventis Pharma Sa | Novel antitumoral use of cabazitaxel |
| US20110237540A1 (en) * | 2009-11-23 | 2011-09-29 | Crawford Thomas C | Cyclodextrin-based polymers for therapeutic delivery |
| WO2011069074A2 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| US9073927B2 (en) | 2010-01-22 | 2015-07-07 | Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii | Inhibitors of PI3 kinase |
| PH12012501662A1 (en) | 2010-02-18 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Triazolo [4,5 - b] pyridin derivatives |
| TWI438009B (zh) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | 紫杉烷前－乳劑調配物及其製造與使用之方法 |
| WO2011121317A1 (en) | 2010-04-01 | 2011-10-06 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors |
| WO2011139899A2 (en) | 2010-05-03 | 2011-11-10 | Teikoku Pharma Usa, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
| WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
| CN103221054A (zh) | 2010-11-17 | 2013-07-24 | 日本化药株式会社 | 新的胞苷类代谢拮抗剂的高分子衍生物 |
| WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| ME02998B (me) | 2011-04-01 | 2018-10-20 | Genentech Inc | Kombinacija акт inhibiтor jedinjenja i abiraterona za upotrebu pri terapeutsкim treтiranjima |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| HRP20220319T1 (hr) | 2011-05-19 | 2022-05-13 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Makrociklički spojevi kao inhibitori protein kinaze |
| WO2012156999A1 (en) | 2011-05-19 | 2012-11-22 | Manu Chaudhary | Ready to use docetaxel formulation |
| WO2013005041A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Tricyclic heterocyclic compounds as kinase inhibitors |
| WO2013004984A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
| WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
| PT2753355T (pt) | 2011-09-08 | 2019-02-01 | Univ New York | Vírus herpes simplex oncolítico e suas utilizações terapêuticas |
| JP5711378B2 (ja) | 2011-09-11 | 2015-04-30 | 日本化薬株式会社 | ブロック共重合体の製造方法 |
| US9745631B2 (en) | 2011-12-20 | 2017-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for diagnosing and treating oncogenic kras-associated cancer |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| US10138479B2 (en) | 2012-05-24 | 2018-11-27 | Dana-Farber Cancer Institute, Inc. | Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer |
| NZ702244A (en) | 2012-06-08 | 2017-06-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| WO2014014518A1 (en) | 2012-07-18 | 2014-01-23 | Dana-Farber Cancer Institute, Inc. | Methods for treating, preventing and predicting risk of developing breast cancer |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| US10238723B2 (en) | 2013-03-14 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer |
| US10130590B2 (en) | 2013-10-01 | 2018-11-20 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer with atovaquone-related compounds |
| UA125575C2 (uk) | 2014-03-21 | 2022-04-27 | Еббві Інк. | Кон'югат, що містить антитіло проти egfr та лікарський засіб |
| US10350264B2 (en) | 2014-03-27 | 2019-07-16 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin |
| MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
| EP3307330B1 (en) | 2015-06-15 | 2021-03-10 | New York University | Method of treatment using oncolytic viruses |
| US10188626B2 (en) | 2015-11-03 | 2019-01-29 | Cipla Limited | Stabilized cabazitaxel formulations |
| SG11201811193TA (en) | 2016-06-08 | 2019-01-30 | Abbvie Inc | Anti-b7-h3 antibodies and antibody drug conjugates |
| US20200002432A1 (en) | 2016-06-08 | 2020-01-02 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| JP2019521973A (ja) | 2016-06-08 | 2019-08-08 | アッヴィ・インコーポレイテッド | 抗ｂｈ７−ｈ３抗体及び抗体薬物コンジュゲート |
| EP3468599A2 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| WO2017214322A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| CN111465389B (zh) | 2017-09-07 | 2022-06-21 | 深圳信立泰药业股份有限公司 | 多西他赛共缀物的药物组合物及制备方法 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0118316A2 (en) * | 1983-03-07 | 1984-09-12 | Lipid Specialties, Inc. | Synthetic phospholipid compounds, their preparation and use |
| EP0253738A1 (fr) * | 1986-07-17 | 1988-01-20 | Rhone-Poulenc Sante | Dérivés du taxol, leur préparation et les compositions pharmaceutiques qui les contiennent |
| RU2027442C1 (ru) * | 1989-09-27 | 1995-01-27 | Сендзю Фармасьютикал Ко., Лтд. | Вещество, обладающее противоопухолевой активностью |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4507217A (en) * | 1983-03-07 | 1985-03-26 | Lipid Specialties, Inc. | Magnetic compositions and magnetic memory devices prepared therefrom |
| US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| FR2678833B1 (fr) * | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
-
1992
- 1992-12-02 FR FR9214501A patent/FR2698543B1/fr not_active Expired - Lifetime
-
1993
- 1993-10-29 CN CN93119653A patent/CN1090170A/zh active Pending
- 1993-10-29 CN CNB021472459A patent/CN1291713C/zh not_active Ceased
- 1993-11-09 MX MX9306986A patent/MX9306986A/es unknown
- 1993-11-22 US US08/155,543 patent/US5438072A/en not_active Expired - Lifetime
- 1993-11-26 EP EP94900881A patent/EP0671912B1/fr not_active Expired - Lifetime
- 1993-11-26 DK DK94900881T patent/DK0671912T3/da active
- 1993-11-26 JP JP50090394A patent/JP3689791B2/ja not_active Expired - Lifetime
- 1993-11-26 AT AT94900881T patent/ATE190838T1/de active
- 1993-11-26 PL PL93309197A patent/PL174334B1/pl unknown
- 1993-11-26 AU AU55669/94A patent/AU691476B2/en not_active Expired
- 1993-11-26 HU HU9501596A patent/HU222833B1/hu active IP Right Maintenance
- 1993-11-26 RU RU95113494A patent/RU2144356C1/ru not_active IP Right Cessation
- 1993-11-26 WO PCT/FR1993/001166 patent/WO1994012171A1/fr not_active Ceased
- 1993-11-26 NZ NZ258150A patent/NZ258150A/en not_active IP Right Cessation
- 1993-11-26 CZ CZ951421A patent/CZ284080B6/cs not_active IP Right Cessation
- 1993-11-26 DE DE69328192A patent/DE69328192D1/de not_active Expired - Lifetime
- 1993-11-26 KR KR1019950702223A patent/KR100330316B1/ko not_active Expired - Fee Related
- 1993-11-26 SK SK725-95A patent/SK281558B6/sk not_active IP Right Cessation
- 1993-11-26 DE DE69328192T patent/DE69328192T4/de not_active Expired - Lifetime
- 1993-11-26 CA CA002150576A patent/CA2150576C/fr not_active Expired - Lifetime
- 1993-11-26 PT PT94900881T patent/PT671912E/pt unknown
- 1993-11-26 ES ES94900881T patent/ES2145115T4/es not_active Expired - Lifetime
- 1993-11-30 TW TW082110084A patent/TW271395B/zh not_active IP Right Cessation
- 1993-11-30 GE GEAP19931662A patent/GEP19991856B/en unknown
- 1993-11-30 ZA ZA938936A patent/ZA938936B/xx unknown
- 1993-12-01 YU YU74593A patent/YU49092B/sh unknown
-
1995
- 1995-05-31 NO NO19952151A patent/NO314436B1/no not_active IP Right Cessation
- 1995-06-01 FI FI952680A patent/FI113619B/fi not_active IP Right Cessation
-
2000
- 2000-03-23 GR GR990401833T patent/GR3032828T3/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0118316A2 (en) * | 1983-03-07 | 1984-09-12 | Lipid Specialties, Inc. | Synthetic phospholipid compounds, their preparation and use |
| EP0253738A1 (fr) * | 1986-07-17 | 1988-01-20 | Rhone-Poulenc Sante | Dérivés du taxol, leur préparation et les compositions pharmaceutiques qui les contiennent |
| RU2027442C1 (ru) * | 1989-09-27 | 1995-01-27 | Сендзю Фармасьютикал Ко., Лтд. | Вещество, обладающее противоопухолевой активностью |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2428175C2 (ru) * | 2008-06-02 | 2011-09-10 | Закрытое Акционерное Общество "Биокад" | Способ получения парентерального фармацевтического раствора |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2144356C1 (ru) | Композиция для инъекций на основе таксоидов | |
| RU2134123C1 (ru) | Фармацевтический состав для инъекций, способ его получения и перфузионный раствор на основе фармацевтического состава | |
| US5698582A (en) | Compositions containing taxane derivatives | |
| HK1006207B (en) | Novel compositions based on taxane class derivatives | |
| US10842770B2 (en) | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same | |
| JP2003503339A (ja) | 抗癌剤を含有する自己乳化システム | |
| EA016619B1 (ru) | Новые композиции на основе таксоидов | |
| JP3917820B2 (ja) | オザグレルナトリウム含有注射液およびその安定化方法 | |
| BG65985B1 (bg) | Метод за получаване на стабилна фармацевтична форма на паклитаксел | |
| RU2481827C2 (ru) | Фармацевтический состав для инъекций, способ его получения и перфузионный раствор на основе фармацевтического состава | |
| HK1075197B (en) | New composition containing taxane derivatives as major component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND4A | Extension of patent duration |
Free format text: CLAIMS: 1,2,7 Extension date: 20181126 |
|
| MF4A | Cancelling an invention patent | ||
| RZ4A | Other changes in the information about an invention | ||
| RZ4A | Other changes in the information about an invention |